Earnings Call · Q2 FY2024·2024-08-07

Q2 24EPS +7.31%·Rev n/aQ1 24EPS -17.52%·Rev n/aQ4 23EPS -6.37%·Rev n/aQ3 23EPS -8.32%·Rev n/a⚠ consensus missing

MADRIGAL PHARMACEUTICALS, INC. MDGL

Tina Ventura — Investor Relations or Communications Officer

Bill Sibold — Chief Executive Officer

Mardi Dier — Chief Financial Officer or Finance Executive

Thomas Smith — Analyst

−12.2%1d on move date−11.5% vs SPY3d−11.1%5d−8.6%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more MDGL calls or request research access.

More MDGL calls Browse calls Request research access